Published in J Rheumatol on April 01, 1999
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med (2007) 2.69
Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung (2010) 1.11
Raynaud's phenomenon in undifferentiated connective tissue disease (UCTD). Clin Rheumatol (2004) 0.87
Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatol Int (2011) 0.82
Undifferentiated connective tissue disease presenting with prevalent interstitial lung disease: case report and review of literature. Diagn Pathol (2011) 0.80
Prevalence of systemic lupus erythematosus in South Korea: an administrative database study. J Epidemiol (2014) 0.76
Serum proteins and paraproteins in women with silicone implants and connective tissue disease: a case-control study. Arthritis Res Ther (2007) 0.75
Longitudinal analysis of quality of life in patients with undifferentiated connective tissue diseases. Patient Relat Outcome Meas (2017) 0.75
[Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems]. Z Rheumatol (2013) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum (1998) 12.36
Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. Ann Intern Med (1995) 5.18
Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis (2005) 4.67
Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. Science (1987) 4.59
A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet (2001) 4.17
Concurrent medical disease in work-related carpal tunnel syndrome. Arch Intern Med (1998) 3.78
Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum (1990) 3.66
A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum (2001) 3.15
Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum (1994) 3.15
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
The role of a signaling protein in bacterial sensing: behavioral effects of increased gene expression. Proc Natl Acad Sci U S A (1984) 2.59
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Chronic proliferative arthritis of mice induced by Mycoplasma arthritidis. I. Induction of disease and histopathological characteristics. Infect Immun (1971) 2.51
Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum (1993) 2.49
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
A 275 basepair fragment at the 5' end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the T cell antigen receptor. J Exp Med (1987) 2.37
The adenovirus major late transcription factor activates the rat gamma-fibrinogen promoter. Science (1987) 2.28
Identification of a bacterial sensing protein and effects of its elevated expression. J Bacteriol (1985) 2.14
Worldwide clinical safety experience with diclofenac. Semin Arthritis Rheum (1985) 2.12
Nocardial infections in the immunocompromised host: A detailed study in a defined population. Rev Infect Dis (1981) 2.03
Effect of Animal Passage on Arthritogenic and Biological Properties of Mycoplasma arthritidis. Infect Immun (1970) 2.00
The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol (1998) 1.97
Reiter's syndrome. Evaluation of preliminary criteria for definite disease. Arthritis Rheum (1981) 1.97
Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum (1998) 1.96
Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (1998) 1.93
Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum (1997) 1.92
Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med (1993) 1.91
Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1985) 1.88
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol (2001) 1.86
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.85
D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med (1982) 1.84
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum (2000) 1.82
Immunological responses of the rat to Mycoplasma arthritidis. J Bacteriol (1969) 1.80
The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res (1991) 1.78
A comparative study on the virulence of Mycoplasma arthritidis and "Mycoplasma hominis, type 2" strains in rats. Proc Soc Exp Biol Med (1967) 1.78
Role of Biological Mimicry in the Pathogenesis of Rat Arthritis Induced by Mycoplasma arthritidis. Infect Immun (1971) 1.75
Interaction of Mycoplasma arthritidis and other mycoplasmas with murine peritoneal macrophages. Infect Immun (1973) 1.74
Characterization of mycoplasma strains from cats. J Bacteriol (1967) 1.72
Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum (1986) 1.72
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study. Ann Rheum Dis (2006) 1.70
Arthritis of mice induced by Mycoplasma pulmonis: humoral antibody and lymphocyte responses of CBA mice. Infect Immun (1975) 1.70
Hemolysin and peroxide activity of Mycoplasma species. J Bacteriol (1968) 1.69
Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum (1987) 1.68
Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1992) 1.62
Tandem duplication and multiple functions of a receptor gene in bacterial chemotaxis. J Biol Chem (1982) 1.61
Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med (1993) 1.61
Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum (2005) 1.58
Patient non-compliance within the context of seeking medical care for arthritis. J Chronic Dis (1973) 1.56
Carcinoid tumors of the gastrointestinal tract. Ann Surg (1974) 1.55
Intracellular Ca2+ stores in chicken Purkinje neurons: differential distribution of the low affinity-high capacity Ca2+ binding protein, calsequestrin, of Ca2+ ATPase and of the ER lumenal protein, Bip. J Cell Biol (1991) 1.54
The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage (2009) 1.54
Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum (1988) 1.54
Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med (1994) 1.50
'Pseudoseptic' arthritis in patients with rheumatoid arthritis. West J Med (1985) 1.49
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum (1984) 1.46
Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) (1983) 1.44
A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum (1998) 1.43
Intravenous pulsed steroids in rheumatoid arthritis: a comparative dose study. J Rheumatol (1990) 1.42
Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. Arthritis Rheum (1985) 1.42
Acute hematogenous osteomyelitis progressing to septic synovitis and eventual pyarthrosis. The vascular pathway. Arthritis Rheum (1979) 1.41
Nerve growth factor gene expression in the developing rat brain. Science (1986) 1.41
Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med (1990) 1.40
Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum (1983) 1.39
Radiographic diagnosis of sacroiliitis--are sacroiliac views really better? J Rheumatol (1998) 1.39
Methylmalonicacidemia: biochemical heterogeneity in defects of 5'-deoxyadenosylcobalamin synthesis. Proc Natl Acad Sci U S A (1975) 1.39
Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients. Transfusion (1991) 1.39
Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol (1990) 1.37
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.35
Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum (1984) 1.35
Chronic arthritis of rabbits induced by mycoplasmas. I. Clinical microbiologic, and histologic features. Arthritis Rheum (1980) 1.35
Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum (1992) 1.33